Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(1):240-255. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0587

View: 957 Download: 157 Crossref: 1

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564

View: 1071 Download: 96

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 969 Download: 129

Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma

Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing

Clin Mol Hepatol. 2025;31(1):196-212. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0527

View: 1035 Download: 148 Web of Science: 1 Crossref: 1

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 1086 Download: 139

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(1):166-178. Published online October 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0484

View: 1024 Download: 110

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Clin Mol Hepatol. 2025;31(1):147-165. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478

View: 2320 Download: 518

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451

View: 1069 Download: 162

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial

Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park

Clin Mol Hepatol. 2025;31(1):119-130. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0629

View: 1147 Download: 203

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(1):105-118. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198

View: 2249 Download: 276 Web of Science: 1 Crossref: 1

Review

Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment

Atsumasa Komori, Yuki Kugiyama

Clin Mol Hepatol. 2025;31(1):90-104. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0821

View: 1040 Download: 180

Viewed By 6278	MAFLD: How is it different from NAFLD?
Viewed By 5057	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4860	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3501	Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Viewed By 3119	Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Cited By 287	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 239	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 161	MAFLD: How is it different from NAFLD?
Cited By 85	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 81	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Topics